Analyzing PTC Therapeutics (NASDAQ:PTCT) & Marker Therapeutics (NASDAQ:MRKR)

PTC Therapeutics (NASDAQ:PTCT) and Marker Therapeutics (NASDAQ:MRKR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Insider and Institutional Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for PTC Therapeutics and Marker Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	1	3	10	1	2.73
Marker Therapeutics	1	0	2	1	2.75

PTC Therapeutics presently has a consensus price target of $99.23, indicating a potential upside of 52.87%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 952.52%. Given Marker Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-9.17%	N/A	-0.10%
Marker Therapeutics	N/A	-56.96%	-47.82%

Volatility & Risk

PTC Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Valuation & Earnings

This table compares PTC Therapeutics and Marker Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73 billion	3.13	$682.64 million	($1.40)	-46.36
Marker Therapeutics	$3.55 million	4.46	-$12.16 million	($0.41)	-2.32

PTC Therapeutics has higher revenue and earnings than Marker Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Marker Therapeutics beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

About PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

About Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors. The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.